Shopping Cart
- Remove All
- Your shopping cart is currently empty
Mirikizumab (LY3074828) is a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), modulating immune response by inhibiting IL-23 binding to IL-23R, used in studies of ulcerative colitis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $213 | In Stock | |
5 mg | $562 | In Stock | |
10 mg | $893 | In Stock | |
25 mg | $1,320 | In Stock | |
50 mg | $1,780 | In Stock |
Description | Mirikizumab (LY3074828) is a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), modulating immune response by inhibiting IL-23 binding to IL-23R, used in studies of ulcerative colitis. |
In vitro | Mirikizumab binds IL-23 in humans and monkeys with high affinity, with Kd values of 21 pM and 55 pM, respectively. [1] |
In vivo | Mirikizumab (4.4 pm-800 nM, 48 h) completely neutralizes IL-17A induced by human and cynocytic monkey IL-23 in mouse spleen cells with IC50 of 82 pM and 120 pM, respectively. [1] |
Alias | LY3074828, LY 3074828 |
Cas No. | 1884201-71-1 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.